Jay Short

Dr. Jay Short

Jay Short is founder and CEO of the antibody drug company BioAtla, LLC .[1] Previously he was VP of Research and Operations at Stratagene (now Agilent Technologies), President of the Stratagene antibody subsidiary Stratacyte, then founder and CEO of Diversa until his departure in 2005.[2] While at Diversa, Dr. Short invented methods of protein and pathway discovery via metagenomics, in addition to key evolution technologies Gene Site Saturation MutagenesisTM (GSSM) and GeneReassemblyTM,[3] and was the first to combine these discovery and evolution technologies.

On December 7, 2015, San Diego-based BioAtla signed a license and option deal with Pfizer, involving BioAtla's patented Conditionally Active Biologics (CAB) antibody platform and Pfizer's Antibody Drug Conjugate (ADC) payloads.[4] Both companies signed the deal in order to advance development and commercialization of a new class of antibody therapeutics. BioAtla is eligible to receive more than $1.0 billion in up-front, regulatory and sales milestone commitments as well as tiered marginal royalties reaching double digits on potential future product sales.[5]

Dr. Short is also founder of the E. O. Wilson Biodiversity Foundation , Chairman of the Board of Ciris Energy ,[6] and member of the Board of Directors of Senomyx.[7] Dr. Short received his Ph.D. in Biochemistry from Case Western Reserve University in Cleveland, Ohio and his B.A. with honors in Chemistry from Taylor University in Upland, Indiana.

References

  1. ↑ http://online.liebertpub.com/doi/abs/10.1089/ind.2007.3.013?journalCode=ind&
  2. ↑ Somers, Terri (October 7, 2005). "Diversa CEO resigns from biotech". The San Diego Union-Tribune. Retrieved 12 August 2011.
  3. ↑ http://www.genengnews.com/media/pdf/sequencing_pdf1.pdf
  4. ↑ "BioAtla Enters Into Strategic License And Option Agreement With Pfizer For A New Class Of Antibody Therapeutics". PR Newswire. 7 December 2015. Retrieved 9 December 2015.
  5. ↑ "ADCs take CAB ride to tumor-town: $1B deal with Pfizer sets Bioatla on development road". BioWorld. 8 December 2015. Retrieved 9 December 2015.
  6. ↑ http://www.sandiegouniontribune.com/news/2013/feb/24/biotech-whizs-methane-mining-technique-could-be/
  7. ↑ "Jay M. Short, Ph.D. Joins the Board of Directors of Senomyx, Inc.". PR Newswire. 13 April 2004. Retrieved 11 May 2016.

External links

This article is issued from Wikipedia - version of the 5/12/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.